Literature DB >> 27832049

Investigation of the First Seven Reported Cases of Candida auris, a Globally Emerging Invasive, Multidrug-Resistant Fungus - United States, May 2013-August 2016.

Snigdha Vallabhaneni, Alex Kallen, Sharon Tsay, Nancy Chow, Rory Welsh, Janna Kerins, Sarah K Kemble, Massimo Pacilli, Stephanie R Black, Emily Landon, Jessica Ridgway, Tara N Palmore, Adrian Zelzany, Eleanor H Adams, Monica Quinn, Sudha Chaturvedi, Jane Greenko, Rafael Fernandez, Karen Southwick, E Yoko Furuya, David P Calfee, Camille Hamula, Gopi Patel, Patricia Barrett, Patricia Lafaro, Elizabeth L Berkow, Heather Moulton-Meissner, Judith Noble-Wang, Ryan P Fagan, Brendan R Jackson, Shawn R Lockhart, Anastasia P Litvintseva, Tom M Chiller.   

Abstract

Candida auris, an emerging fungus that can cause invasive infections, is associated with high mortality and is often resistant to multiple antifungal drugs. C. auris was first described in 2009 after being isolated from external ear canal discharge of a patient in Japan (1). Since then, reports of C. auris infections, including bloodstream infections, have been published from several countries, including Colombia, India, Israel, Kenya, Kuwait, Pakistan, South Africa, South Korea, Venezuela, and the United Kingdom (2-7). To determine whether C. auris is present in the United States and to prepare for the possibility of transmission, CDC issued a clinical alert in June 2016 informing clinicians, laboratorians, infection control practitioners, and public health authorities about C. auris and requesting that C. auris cases be reported to state and local health departments and CDC (8). This report describes the first seven U.S. cases of C. auris infection reported to CDC as of August 31, 2016. Data from these cases suggest that transmission of C. auris might have occurred in U.S. health care facilities and demonstrate the need for attention to infection control measures to control the spread of this pathogen.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27832049     DOI: 10.15585/mmwr.mm6544e1

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  64 in total

1.  Preparing your healthcare facility for the new fungus among us: An infection preventionist's guide to Candida auris.

Authors:  Tina Z Wang; Kindra N White; Jillian Villani Scarr; Matthew S Simon; David P Calfee
Journal:  Am J Infect Control       Date:  2020-07       Impact factor: 2.918

2.  In Vitro Activity of a Novel Glucan Synthase Inhibitor, SCY-078, against Clinical Isolates of Candida auris.

Authors:  Elizabeth L Berkow; David Angulo; Shawn R Lockhart
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

Review 3.  Idiopathic, Infectious and Reactive Lesions of the Ear and Temporal Bone.

Authors:  Kelly R Magliocca; Esther X Vivas; Christopher C Griffith
Journal:  Head Neck Pathol       Date:  2018-08-01

Review 4.  Candida auris: a Review of the Literature.

Authors:  Anna Jeffery-Smith; Surabhi K Taori; Silke Schelenz; Katie Jeffery; Elizabeth M Johnson; Andrew Borman; Rohini Manuel; Colin S Brown
Journal:  Clin Microbiol Rev       Date:  2017-11-15       Impact factor: 26.132

5.  Invasive Candida auris infections in Kuwait hospitals: epidemiology, antifungal treatment and outcome.

Authors:  Ziauddin Khan; Suhail Ahmad; Khalifa Benwan; Prashant Purohit; Inaam Al-Obaid; Ritu Bafna; Maha Emara; Eiman Mokaddas; Aneesa Ahmed Abdullah; Khaled Al-Obaid; Leena Joseph
Journal:  Infection       Date:  2018-06-14       Impact factor: 3.553

6.  The Novel Arylamidine T-2307 Demonstrates In Vitro and In Vivo Activity against Candida auris.

Authors:  Nathan P Wiederhold; Laura K Najvar; Rosie Jaramillo; Marcos Olivo; Hoja Patterson; April Connell; Yoshiko Fukuda; Junichi Mitsuyama; Gabriel Catano; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

7.  Antifungal Susceptibility Testing Practices at Acute Care Hospitals Enrolled in the National Healthcare Safety Network, United States, 2011-2015.

Authors:  Snigdha Vallabhaneni; Mathew Sapiano; Lindsey M Weiner; Shawn R Lockhart; Shelley Magill
Journal:  Open Forum Infect Dis       Date:  2017-08-16       Impact factor: 3.835

Review 8.  What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead.

Authors:  Matteo Bassetti; Elda Righi; Philippe Montravers; Oliver A Cornely
Journal:  J Antimicrob Chemother       Date:  2018-01-01       Impact factor: 5.790

Review 9.  Emerging Infections and Pertinent Infections Related to Travel for Patients with Primary Immunodeficiencies.

Authors:  Kathleen E Sullivan; Hamid Bassiri; Ahmed A Bousfiha; Beatriz T Costa-Carvalho; Alexandra F Freeman; David Hagin; Yu L Lau; Michail S Lionakis; Ileana Moreira; Jorge A Pinto; M Isabel de Moraes-Pinto; Amit Rawat; Shereen M Reda; Saul Oswaldo Lugo Reyes; Mikko Seppänen; Mimi L K Tang
Journal:  J Clin Immunol       Date:  2017-08-07       Impact factor: 8.317

10.  Candidemia in Adults at a Tertiary Hospital in China: Clinical Characteristics, Species Distribution, Resistance, and Outcomes.

Authors:  Shaoming Lin; Ruilan Chen; Song Zhu; Huijun Wang; Lianfang Wang; Jian Zou; Jingdong Yan; Xiangdong Zhang; Dimitrios Farmakiotis; Xiaojiang Tan; Eleftherios Mylonakis
Journal:  Mycopathologia       Date:  2018-03-23       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.